SELLAS is a late-stage clinical
biopharmaceutical company...

...focused on the development
of novel therapies for a
broad range of cancer indications

About SELLAS Life Sciences Group

We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a cancer immunotherapeutic agent that targets the Wilms tumor 1, or WT1, protein, and SLS009, a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Our Science

Galinpepimut-S: WT1 Targeting Immunotherapeutic

SLS009: Highly Selective CDK9 Inhibitor

What’s in our Pipeline

SELLAS’ cancer programs target diverse indications in hematological cancers and solid tumors.

What’s in our Pipeline

Latest News